Zevra Therapeutics, Inc. Insider Trading

ZVRA

Last 12 months

Insiders sold $2.52M and bought nothing on the open market.

95% of the selling was scheduled in advance under 10b5-1 plans. Director Corey Michael Watton sold 138K on Aug 10, 87% of their stake, outside a plan. The last open-market buy by an executive or director was in Sep 2025.

Net open-market

−$2.52M

0 buys · 13 sales

Under a 10b5-1 plan

95%

of the value sold

Insiders who bought / sold

0 / 6

executives and directors

Last open-market buy

Sep 2025

Sep 12, 2025

Get an email when ZVRA's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Oct 12	Neil F. McFarlane President and CEO	Sold10b5-1 plan	20,000	$11.25	225K	4.6%	Form 4
Aug 14	Rahsaan Thompson Chief Legal & Compliance	Sold10b5-1 plan	42,666	$11.13	475K	53%	Form 4
Aug 10	Corey Michael Watton Director	SoldNo plan	12,300	$11.25	138K	87%	Form 4
Jun 22	Rahsaan Thompson Chief Legal & Compliance	Sold10b5-1 plan	34,557	$12.68	438K	30%	Form 4
May 11	Rahsaan Thompson Chief Legal & Compliance	Sold10b5-1 plan	1,794	$11.30	20K	3.6%	Form 4
Feb 9	Neil F. McFarlane President and CEO	Sold10b5-1 plan	14,625	$8.56	125K	3.6%	Form 4
Feb 3	Joshua Schafer CCO	Sold10b5-1 plan	10,500	$9.19	96K	14%	Form 4
Feb 3	Timothy J. Sangiovanni SVP, Finance & Corp Controller	Sold10b5-1 plan	3,000	$9.18	28K	9.2%	Form 4
Feb 2	Neil F. McFarlane President and CEO	Sold10b5-1 plan	91,000	$9.38	854K	20%	Form 4
Jan 30	Joshua Schafer CCO	Sold10b5-1 plan	3,375	$8.83	30K	4.4%	Form 4
Jan 30	Adrian W Quartel Chief Medical Officer	Sold10b5-1 plan	4,533	$8.83	40K	32%	Form 4
Jan 30	Rahsaan Thompson Chief Legal & Compliance	Sold10b5-1 plan	4,080	$8.83	36K	7.6%	Form 4
Jan 30	Timothy J. Sangiovanni SVP, Finance & Corp Controller	Sold10b5-1 plan	1,750	$8.82	15K	5.1%	Form 4
Oct 10, 2025	Neil F. McFarlane President and CEO	Sold10b5-1 plan	19,500	$10.82	211K	8.1%	Form 4
Sep 12, 2025	Tamara A Favorito Director	Bought	3,175	$7.79	25K	442%	Form 4
Sep 12, 2025	Alvin Shih Director	Bought	20,000	$7.89	158K	New	Form 4
Aug 19, 2025	John B Bode Director	Bought	5,000	$9.17	46K	13%	Form 4
Jun 26, 2025	Rahsaan Thompson Chief Legal & Compliance	Sold10b5-1 plan	24,000	$9.21	221K	36%	Form 4
Mar 28, 2025	Corey Michael Watton Director	Bought	300	$7.84	2K	20%	Form 4
Mar 19, 2025	John B Bode Director	Bought	10,000	$7.96	80K	33%	Form 4
Feb 13, 2025 – Feb 14, 2025	Neil F. McFarlane President and CEO	Sold10b5-1 plan 2 parts	91,817	$7.92 average	727K	32%	Form 4
Feb 13, 2025	Timothy J. Sangiovanni SVP, Finance & Corp Controller	Sold10b5-1 plan	3,000	$7.86	24K	16%	Form 4
Feb 13, 2025	Joshua Schafer CCO & EVP, Bus. Development	Sold10b5-1 plan	10,500	$7.86	83K	26%	Form 4
Feb 13, 2025	R. Laduane Clifton CFO & Treasurer	Sold10b5-1 plan	11,000	$7.86	86K	18%	Form 4

Oct 1210b5-1 plan
Neil F. McFarlane
President and CEO · sold 20,000 at $11.25
225K
4.6% of stake
Aug 1410b5-1 plan
Rahsaan Thompson
Chief Legal & Compliance · sold 42,666 at $11.13
475K
53% of stake
Aug 10No plan
Corey Michael Watton
Director · sold 12,300 at $11.25
138K
87% of stake
Jun 2210b5-1 plan
Rahsaan Thompson
Chief Legal & Compliance · sold 34,557 at $12.68
438K
30% of stake
May 1110b5-1 plan
Rahsaan Thompson
Chief Legal & Compliance · sold 1,794 at $11.30
20K
3.6% of stake
Feb 910b5-1 plan
Neil F. McFarlane
President and CEO · sold 14,625 at $8.56
125K
3.6% of stake
Feb 310b5-1 plan
Joshua Schafer
CCO · sold 10,500 at $9.19
96K
14% of stake
Feb 310b5-1 plan
Timothy J. Sangiovanni
SVP, Finance & Corp Controller · sold 3,000 at $9.18
28K
9.2% of stake
Feb 210b5-1 plan
Neil F. McFarlane
President and CEO · sold 91,000 at $9.38
854K
20% of stake
Jan 3010b5-1 plan
Joshua Schafer
CCO · sold 3,375 at $8.83
30K
4.4% of stake
Jan 3010b5-1 plan
Adrian W Quartel
Chief Medical Officer · sold 4,533 at $8.83
40K
32% of stake
Jan 3010b5-1 plan
Rahsaan Thompson
Chief Legal & Compliance · sold 4,080 at $8.83
36K
7.6% of stake
Jan 3010b5-1 plan
Timothy J. Sangiovanni
SVP, Finance & Corp Controller · sold 1,750 at $8.82
15K
5.1% of stake
Oct 10, 202510b5-1 plan
Neil F. McFarlane
President and CEO · sold 19,500 at $10.82
211K
8.1% of stake
Sep 12, 2025
Tamara A Favorito
Director · bought 3,175 at $7.79
25K
442% of stake
Sep 12, 2025
Alvin Shih
Director · bought 20,000 at $7.89
158K
New position
Aug 19, 2025
John B Bode
Director · bought 5,000 at $9.17
46K
13% of stake
Jun 26, 202510b5-1 plan
Rahsaan Thompson
Chief Legal & Compliance · sold 24,000 at $9.21
221K
36% of stake
Mar 28, 2025
Corey Michael Watton
Director · bought 300 at $7.84
2K
20% of stake
Mar 19, 2025
John B Bode
Director · bought 10,000 at $7.96
80K
33% of stake
Feb 13, 2025 – Feb 14, 202510b5-1 plan
Neil F. McFarlane
President and CEO · sold 91,817 at avg $7.92
727K
32% of stake
Feb 13, 202510b5-1 plan
Timothy J. Sangiovanni
SVP, Finance & Corp Controller · sold 3,000 at $7.86
24K
16% of stake
Feb 13, 202510b5-1 plan
Joshua Schafer
CCO & EVP, Bus. Development · sold 10,500 at $7.86
83K
26% of stake
Feb 13, 202510b5-1 plan
R. Laduane Clifton
CFO & Treasurer · sold 11,000 at $7.86
86K
18% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch ZVRA, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Pharmaceutical Preparations · Pick stocks to compare with ZVRA

CompareIntrinsic value

KPTIKaryopharm Therapeutics Inc.

$0.07-17.16%15

HRTXHeron Therapeutics Inc.

$0.30+7.14%36

ELTPElite Pharmaceuticals Inc.

$0.25+3.29%89

DAWNDay One Biopharmaceuticals, Inc.

No recent price10

NUVBNuvation Bio Inc.

$4.73+0.85%10

AMRNAmarin Corp PLC\Uk

$12.25+1.66%46

RCUSArcus Biosciences Inc.

$19.31+2.12%10

SPRYArs Pharmaceuticals Inc

$3.05+0.00%40

Held by ETFs

ZVRA is in 26 US ETFs. The largest of them, with ZVRA's weight in each:

Spot a number that looks wrong? Check it in ZVRA's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing ZVRA

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.